Abstracts tagged "Biologics"

Abstract Number: 1546 • 2016 ACR/ARHP Annual Meeting
Clinical Features at the Onset of Lymphoproliferative Disorder in Patients with Rheumatoid Arthritis
Daisuke Kobayashi^1,2, Satoshi Ito¹, Chinatsu Takai^1,3, Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³Department of clinical rheumatology and nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: Rheumatoid arthritis (RA) is intrinsically associated with an increased incidence of lymphoproliferative disorders (LPDs). Although treatment with immunosuppressive agents, such as methotrexate, tacrolimus, or…
Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Kim Papp¹, Alice B. Gottlieb², Catherine L. Shuler³, Russel T. Burge³, Gregory Cameron³, Lisa Kerr³ and Philip J Mease⁴, ¹K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ²Tufts University School of Medicine, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 3149 • 2016 ACR/ARHP Annual Meeting
“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Stephanie Gottheil¹, J Carter Thorne², Orit Schieir³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, Diane Tin⁷, Cheryl Barnabe⁸, Glen Hazlewood⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰, Janet E. Pope¹¹, Susan J. Bartlett¹² and Canadian Early Arthritis Cohort, ¹University of Western Ontario, LONDON, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³McGill University, Montreal, ON, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Institute de Rheumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: Optimal treatment for moderate-severe early rheumatoid arthritis involves using a methotrexate-based, treat-to-target strategy aiming for remission. Achieving remission without using biologics may be preferable…
Abstract Number: 358 • 2016 ACR/ARHP Annual Meeting
Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California
Purva Chhibar¹ and Glenn Ehresmann², ¹Internal Medicine, Division of Rheumatology, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA, ²Internal Medicine, Division of Rheumatology, University of Southern Californnia, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: Patients with autoimmune diseases are at increased risk of early onset osteoporosis due to multiple reasons including prolonged exposure to corticosteroids and the disease…
Abstract Number: 1612 • 2016 ACR/ARHP Annual Meeting
Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo², Maiko Yoshikawa², Yusuke Miyazaki², Ippei Miyagawa³, Shigeru Iwata⁴, Kazuhisa Nakano⁵, Kazuyoshi Saito^6,7 and Yoshiya Tanaka⁸, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, KItakyushu, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality associated…
Abstract Number: 2052 • 2016 ACR/ARHP Annual Meeting
Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort
Michael D. George¹, Joshua F. Baker¹, Jesse Yenchih Hsu², Qufei Wu³, Fenglong Xie⁴, Lang Chen⁴, Huifeng Yun⁵ and Jeffrey Curtis⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients taking biologic DMARDs often undergo elective surgery, but data to guide if and when to hold biologics before surgery is limited. This study…
Abstract Number: 3194 • 2016 ACR/ARHP Annual Meeting
Factors Related to Physicians’ Prescriptions for Rheumatoid Arthritis Drugs Never Filled or Subsequently Discontinued By Patients
Hong J. Kan¹, Kirill Dyagilev¹, Peter Schulam², Suchi Saria¹, Charles Molta³ and Jeffrey Curtis⁴, ¹John Hopkins University, Baltimore, MD, ²Department of Computer Science, Johns Hopkins University, Baltimore, MD, ³Sun Pharmaceutical, Cranbury, NJ, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatologists have many choices of medications to use for patients with rheumatoid arthritis (RA), but patients may not fill a prescription (primary non-adherence or…
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 2172 • 2016 ACR/ARHP Annual Meeting
Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Helga Radner¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies have suggested that the chronic inflammatory nature of rheumatic conditions (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) as well as psoriasis (PsO) may…
Abstract Number: 3224 • 2016 ACR/ARHP Annual Meeting
Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Yoshiya Tanaka¹, Daniel Aletaha², Clifton Bingham III³, Prasheen Agarwal⁴, Regina Kurrasch⁵ and Sharon Popik⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: A global, phase 3 study (SIRROUND-T) evaluating the efficacy and safety of sirukumab, a selective, high-affinity human monoclonal antibody to IL-6, has recently been…
Abstract Number: 600 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Dennis Parenti¹, George W. Reed², Ying Shan², Kimberly Dandreo², Joel M. Kremer³ and Raphael J. DeHoratius⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³Albany Medical College, Albany, NY, ⁴Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA
Background/Purpose: Dose escalation is a common strategy for patients (pts) on infliximab (IFX). This study examined the trend in disease activity across dose escalations to…
Abstract Number: 1627 • 2016 ACR/ARHP Annual Meeting
Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Steve Peterson¹, Maud Pacou², Drifa Belhadi², Suzy Van Sanden¹, Thomas Webb¹, Rita Ganguly³, Regina Kurrasch³, Ravi Rao³, Benjamin Hsu¹, Kaiyin Fei¹, Danuta Kielar¹ and Rafael Alfonso³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Amaris, Paris, France, ³GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human anti-interleukin-6 cytokine monoclonal antibody evaluated for the treatment of moderate to severe active rheumatoid arthritis (RA) and other diseases. Our…
Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Ben Roberts¹, Alexander Langridge², John Wilkinson³, Elliot Jones⁴, Edward Lea², Ben Hargreaves⁵, David Walker⁶ and Martin Lee³, ¹Rheumatology, Newcastle University, Newcastle, United Kingdom, ²Rheumatology, Freeman Hospital, Newcastle, United Kingdom, ³Freeman Hospital, Newcastle, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶Rake Lane, Northumbria Healthcare, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting
Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Mark C. Genovese¹, Michael Weinblatt², Heikki T. Mansikka³, Paul M. Peloso³, Kun Chen³, Yihan Li³, John Liu³ and Robert J. Padley³, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].